Untch 2008.

Methods	randomized controlled trial, not placebo‐controlled
Participants	n = 729, breast cancer (M0); concomitant treatment: chemotherapy
Interventions	drug = Darbepoetin alpha dose = 4.5 µg/kg sc Q2W hb‐target = 13 g/dL planned ESA duration = during chemotherapy
Outcomes	Primary: relapse free survival time, overall survival; secondary: tumor control, safety and tolerability, transfusion, Hb level, QoL
Notes	study number = 66960
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	no description
Allocation concealment?	Unclear risk	description is unclear